Italia markets closed

AIM ImmunoTech Inc. (0A4Y.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,4700-0,3300 (-41,25%)
Alla chiusura: 07:13PM GMT

AIM ImmunoTech Inc.

2117 SW Highway 484
Ocala, FL 34473
United States
352 448 7797
https://www.aimimmuno.com

Settore/i
Settore
Impiegati a tempo pieno21

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Thomas K. Equels Esq., J.D., M.S.Exec. Vice Chairman, CEO & Pres1,29MN/D1953
Mr. Peter W. Rodino III, Esq., J.D.COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec.585,45kN/D1951
Mr. Robert Dickey IV, M.B.A.Chief Financial OfficerN/DN/D1956
Dr. David R. Strayer M.D.Chief Scientific Officer & Medical DirectorN/DN/D1946
Ann Marie E. CoverlyDirector of Admin. & HR and Deputy Investor Relations CoordinatorN/DN/DN/D
Dr. Carol A. SmithChief Manufacturing Officer & Deputy Chief Scientific OfficerN/DN/D1951
Jodie PelzControllerN/DN/DN/D
Dr. Ralph Christopher Cavalli Ph.D.VP of QC & ManufacturingN/DN/D1958
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Governance aziendale

L'ISS Governance QualityScore di AIM ImmunoTech Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.